FDA strategies to prevent and respond to drug shortages: finding a better way to predict and prevent company closures.
To stave off a shortage of doxorubicin in 2011 and 2012, the FDA expedited the approval of a company's unapproved manufacturing process. Paying companies sufficiently so that they can invest in their facilities when needed is just one of many steps that could be taken to rectify future shortages.
Mr. Barlas, a freelance writer based in Washington, D.C., covers topics inside the Beltway.
Stephen
S
Barlas